Document is current

Article History

Received: 18 March 2025

Accepted: 4 June 2025

First Online: 30 June 2025

Declarations

:

: Hidekazu Suzuki reports having financial interests, payment for lectures including service on speakers’ bureaus from Eli Lilly, MSD, Chugai, AstraZeneca. Akito Hata reports receiving research grants from MSD, Eli Lilly, Chugai, Taiho, Boehringer Ingelheim, AstraZeneca, AbbVie. Akito Hata reports having financial interests, payment for lectures including service on speakers’ bureaus from Eli Lilly, MSD, Chugai, Pfizer, AstraZeneca, Boehringer Ingelheim, Taiho. Takaaki Tokito reports having financial interests, payment for lectures including service on speakers’ bureaus from AstraZeneca, Ono Pharmaceutical, MSD Oncology, Chugai Pharma, Bristol Myers Squibb, Nippon Kayaku, Boehringer Ingelheim. Kana Watanabe reports having financial interests, payment for lectures including service on speakers’ bureaus from AstraZeneca K.K. Tatsuro Fukuhara have no conflicts of interest to declare. Yoshiaki Zaizen reports having financial interests, payment for lectures including service on speakers’ bureaus from Boehringer Ingelheim Co., Ltd. Toshihide Yokoyama Toshihide Yokoyama reports receiving research grants from AbbVie GK, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Delta-Fly Pharma, Janssen, MSD, Parexel International, Takeda. Toshihide Yokoyama reports having financial interests, payment for lectures including service on speakers’ bureaus from AstraZeneca, Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly, Merck Biopharma, MSD, Nippon Kayaku, Novartis, Ono Pharmaceutical, Pfizer, Takeda. Yasushi Fukuda reports receiving research grants from Novartis Pharma, Parexel International Inc. Yasushi Fukuda reports having financial interests, payment for lectures including service on speakers’ bureaus from AstraZeneca, Chugai Pharma, MSD, Merck Biopharma, Ono Pharmaceutical, Bristol-Myers Squibb, Eli Lilly, Boehringer Ingelheim, Novartis Pharma, Takeda Pharmaceutical. Takayuki Shiroyama has no conflicts of interest to declare. Yoshihiro Amano has no conflicts of interest to declare. Akane Ishida have no conflicts of interest to declare. Akiyoshi Nakakura has no conflicts of interest to declare. Satoshi Morita reports having financial interests, payment for lectures including service on speakers’ bureaus from AstraZeneca K.K., Bristol-Myers Squibb Company, Chugai Pharmaceutical Co. Ltd, Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd. Yukimasa Hatachi has no conflicts of interest to declare. Nobuyuki Katakami reports receiving research grants from Astra Zeneca, Chugai Pharmaceutical, Delta-Fly Pharma, MSD, Ono Pharmaceutical, AbbVie, Glaxo Smith Kline. Nobuyuki Katakami reports having financial interests, payment for lectures including service on speakers’ bureaus from Astra Zeneca, Chugai Pharmaceutical, Takeda Pharmaceutical, Ono Pharmaceutical, MSD, Bristol Myers Squib, Kyorin Pharmaceutical, Kyowa Kirin, Boehringer Ingelheim, Taiho Pharmaceutical. Funding The Kobe City General Hospital Scientific Fund supported this study.

: University Hospital Medical Information Network (UMIN: 000018248).